Jad Chahoud Highlights a Study on Triple therapy in MSS BRAFV600E mCRC
Jad Chahoud, Associate Member, Department of Genitourinary Oncology at Moffitt Cancer Center, shared a post on X about an article Van K. Morris and colleagues authored:
“Triple therapy in MSS BRAFV600E mCRC:
BRAF inhibitor (encorafenib) + EGFR blockade (cetuximab) + PD-1 (nivolumab) → 50% ORR & median PFS 7.4 mo.
• Immune & MAPK activation = responders
• Complement activation = resistance.”
Title: Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
Authors: Van K. Morris, Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal, Kangyu Lin, Kanwal P.S. Raghav, Robert A. Wolff, Arvind Dasari, Ryan W. Huey, Bryan K. Kee, Michael J. Overman, Jason A. Willis, Phat H. Le, Michelle Escano, Yunyu C. Baig, Kelsey Pan, David Menter, Alda L. Tam, Wai C. Foo, Li Shen, Hey Min Lee, Thomas D. Gallup, Cori Margain, Dave Gallup, Kimal I. Rajapakshe, Paola A. Guerrero, Jing Wang, Ryan B. Corcoran, Anirban Maitra, Kyuson Yun, Scott Kopetz
More posts featuring Jad Chahoud.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023